Abstract
Background: Upper respiratory tract infections (URTIs) account for at least half of all acute illnesses. Specific antiviral therapy has not been developed against most respiratory viruses thought to cause URTIs. The pharmacologic action of glycyrrhizin has been shown to produce anti-inflammatory activity, modulation of the immune system, inhibition of virus growth, and inactivation of viruses.
Objective: The aim of this study was to assess the tolerability, efficacy, and cost of glycyrrhizin in improving the severity and duration of signs and symptoms of URTIs. The primary end point was tolerability, and the secondary and points included improvement in signs and symptoms of URTI and cost.
Methods: Members of the Japanese Maritime Self-Defense Force (SDF) treated for URTIs from January 2002 to May 2002 in the SDF Etajima Hospital (Hiroshima, Japan) were eligible for this prospective, randomized, double-blind, controlled, parallel-group, alternate-day treatment assignment study. All patients in this study fulfilled the following enrollment criteria: admitted to the hospital on the first arrival day as an outpatient; fever (body temperature <38.0°C) with signs and symptoms of URTI (headache, sore throat, rhinorrhea, pharyngitis); and had not received antibiotics or oseltamivir phosphate for 4 weeks before the study. Patients who were admitted on an even day received an IV drip infusion of 40 mL of glycyrrhizin (0.2%) and 500 mL of lactated Ringer's solution daily during hospitalization (glycyrrhizin group). Patients who were admitted on an odd day received an IV drip infusion of 500 mL/d of lactated Ringer's solution only (control group). Adverse effects were assessed by the physicians during hospitalization, using patient interview and laboratory analysis.
Results: Forty-one consecutive patients entered the study; 15 patients (15 men, 0 women; mean [SD] age, 25.2 [1.5] years) were assigned to the glycyrrhizin group and 269 patients (24 men, 2 women; mean [SD] age, 22.6 [0.9] years) were assigned to the control group. The 2 groups were similar in terms of baseline characteristics. The mean duration of hospitalization was shorter (P = 0.01), the mean maximum body temperature 24 to 48 hours after admission was less (P = 0.05), and the cost of therapy (P = 0.03) was less in the glycyrrhizin group than the control group. No AEs were reported.
Conclusions: In this study of hospitalized patients with URTIs, glycyrrhizin therapy was associated with a shorter hospitalization, lower-grade fever, and lower cost of therapy compared with controls, showing that it may be beneficial to patients with URTIs without acute bacterial infections.
Keywords: common cold, upper respiratory tract infection, glycyrrhizin, outcome
Full Text
The Full Text of this article is available as a PDF (396.5 KB).
References
- 1.Dolin R. Common viral respiratory infections. In: Fauci A.S, Braumwald E, Isselbacher K.J, editors. Harrison's Principles of Internal Medicine. McGraw-Hill; New York: 1998. pp. 1100–1105. [Google Scholar]
- 2.Gwaltney J.M. Viral respiratory infection therapy: Historical perspectives and current trials. Am J Med. 2002;112(Suppl 6A):33S–41S. doi: 10.1016/s0002-9343(01)01062-2. [DOI] [PubMed] [Google Scholar]
- 3.Sugaya N. Influenza vaccine, anti-influenza drugs, and rapid diagnosis in Japan. J Infect Chemother. 2000;6:77–80. doi: 10.1007/pl00012155. [DOI] [PubMed] [Google Scholar]
- 4.Ohtsuki K, Abe Y, Shimoyama Y. Separation of phospholipase A2 in Habu snake venom by glycyrrhizin (GL)-affinity column chromatography and identification of a GL-sensitive enzyme. Biol Pharm Bull. 1998;21:574–578. doi: 10.1248/bpb.21.574. [DOI] [PubMed] [Google Scholar]
- 5.Shimoyama Y, Ohtaka H, Nagata N. Physiological correlation between glycyrrhizin, glycyrrhizin-binding lipoxygenase and casein kinase II. FEBS Lett. 1996;391:238–242. doi: 10.1016/0014-5793(96)00744-2. [DOI] [PubMed] [Google Scholar]
- 6.Zhang Y.H, Isobe K, Iwamoto T, Nakashima I. Bidirectional control by glycyrrhizin of the growth response of lymphocytes stimulated through a receptor-bypassed pathway. Immunol Lett. 1992;32:147–152. doi: 10.1016/0165-2478(92)90107-y. [DOI] [PubMed] [Google Scholar]
- 7.Kimura M, Watanabe H, Abo T. Selective activation of extrathymic T cells in the liver by glycyrrhizin. Biotherapy. 1992;5:167–176. doi: 10.1007/BF02171049. [DOI] [PubMed] [Google Scholar]
- 8.Iijima N, Yamamoto T, Gomi F, Kojima Y. Antivirus action of stronger neominophagen C · glycyrrhizin. Minophagen Med Rev. 1970;15:121–122. [Google Scholar]
- 9.Pompei R, Flore O, Marccialis M.A. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature. 1979;281:689–690. doi: 10.1038/281689a0. [DOI] [PubMed] [Google Scholar]
- 10.Baba M, Shigeta S. Antiviral activity of glycyrrhizin against varicella-zoster virus in vitro. Antiviral Res. 1987;7:99–107. doi: 10.1016/0166-3542(87)90025-8. [DOI] [PubMed] [Google Scholar]
- 11.Cinatl J, Morgenstern B, Bauer G. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361:2045–2046. doi: 10.1016/S0140-6736(03)13615-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Kasai T. Stronger neo-minophagen C for common colds. Shinryo to Shinyaku. 1965;2:127–130. [Google Scholar]
- 13.Kaji S, Kashiwagi S, Hayashida K. Evaluation of PL® in the treatment of common colds. Rinsho to Kenkyu. 1977;54:205–213. [Google Scholar]
- 14.Yoshihara N, Shouji H. Inactivation of HIV by disinfectant. Konnichi no Kansensho. 1988;7:10. [Google Scholar]
- 15.Iryo-Hoken-Gyomu-Kenyu-Kyokai; Tokyo, Japan: 2002. Hinryo-Hoshu-to-Hayamihyo. [Google Scholar]
- 16.Huttunen T, Teppo A.-M, Lupisan S. Correlation between the severity of infectious diseases in children and the ratio of serum amyloid A protein and C-reactive protein. Scand J Infect Dis. 2003;35:488–490. doi: 10.1080/00365540310012235. [DOI] [PubMed] [Google Scholar]
- 17.Luzzani A, Polati E, Dorizzi R. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 2003;31:1737–1741. doi: 10.1097/01.CCM.0000063440.19188.ED. [DOI] [PubMed] [Google Scholar]